Evidence map›Paper›PMID 40608264›Full record

ArticleOphthalmology and therapy2025

Functional and Anatomical Outcomes of Faricimab in Previously Treated Wet Age-Related Macular Degeneration: Systematic Review and Pooled Analysis.

Ali Khodor, Jonathan T Caranfa, Tavish Nanda, Raul E Ruiz-Lozano, Manuel E Quiroga-Garza, Stephanie Choi, Ali Chehab, Eugenia M Ramos-Dávila, Jeffrey S Heier, Chirag P Shah and 1 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ali KhodorBascom Palmer Eye Institute, University of Miami, Miami, FL, USA.ORCID http://orcid.org/0009-0004-8752-919X
Jonathan T CaranfaNew England Eye Center, Department of Ophthalmology, Tufts University Medical Center, Boston, MA, USA.
Tavish NandaRetina Consultants, P.C., Hartford, CT, USA.
Raul E Ruiz-LozanoBascom Palmer Eye Institute, University of Miami, Miami, FL, USA.ORCID http://orcid.org/0000-0001-7022-2395
Manuel E Quiroga-GarzaBascom Palmer Eye Institute, University of Miami, Miami, FL, USA.ORCID http://orcid.org/0000-0002-5237-240X
Stephanie ChoiNew England Eye Center, Department of Ophthalmology, Tufts University Medical Center, Boston, MA, USA.
Ali ChehabDepartment of Physiology, Wayne State University School of Medicine, Detroit, MI, USA.
Eugenia M Ramos-DávilaTecnologico de Monterrey, School of Medicine and Health Sciences, Institute of Ophthalmology and Visual Sciences, Monterrey, Mexico.
Jeffrey S HeierOphthalmic Consultants of Boston, 50 Staniford Street, Suite 600, Boston, MA, 02114, USA.
Chirag P ShahOphthalmic Consultants of Boston, 50 Staniford Street, Suite 600, Boston, MA, 02114, USA.ORCID http://orcid.org/0000-0001-6369-4917
Andre J WitkinNew England Eye Center, Department of Ophthalmology, Tufts University Medical Center, Boston, MA, USA. ajwitkin@gmail.com.ORCID http://orcid.org/0000-0002-3001-8098

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo evaluate the outcomes of intravitreal faricimab (IVF; Vabysmo

methodsThe PubMed, Embase, and Google Scholar databases were searched for studies reporting outcomes of treatments for previously treated cases of wAMD. Mean differences (MD) with 95% confidence intervals (CI) were used to compute the effect size of the change in outcomes.

resultsA total of 29 studies with 2070 patients (1003 women, mean age 78.9 years) and 2128 eyes were included. BAVA and CST were reported in 28 studies, fluid status in 21, injection interval in 14, and reversion rates in 6. Pooled analysis showed significant but modest improvement in BAVA when IVF was given for > 6 months (MD = -0.026 LogMAR, p < 0.05) but not at earlier follow-ups. A similar trend was noted with injection interval extension when IVF was given beyond 6 months (MD = +2.1 weeks, p < 0.05). CST reduction was observed at all time points (overall MD = -37.7 μm, p < 0.05). Complication rates were reported in nine studies, with an overall rate of 1.2%, including retinal pigment epithelium tear, intraocular inflammation, endophthalmitis, and subretinal hemorrhage. Reversion to prior or other anti-vascular endothelial growth factor (anti-VEGF) therapy was reported in six studies, occurring in 23% of eyes.

conclusionsWe reported the outcomes of utilizing IVF in previously treated cases of wAMD. IVF showed a significant improvement in CST at all time points and in the extension of injection interval. Visual outcomes remained unchanged when followed for less than 6 months but improved significantly but modestly when followed for more than 6 months. Switching to intravitreal faricimab may be a useful treatment option for previously treated patients with wAMD, with a goal of reducing treatment burden and improving treatment efficacy.

Indexed as

Age-related macular degenerationAMDAnti-VEGFFaricimabIntravitreal therapyRetinaTreatment

Identifiers

PMID40608264
PMCPMC12271014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.